IFNB1 and Miyoshi myopathy: Based on these results, a phase I trial was created to investigate the best dose and side effects of VSV-(h)IFNβ-NIS in the treatment of relapsed or unresponsive patients with MM, acute myeloid leukemia, or T-cell lymphoma (NCT03017820).